Clarify the Role of Monoclonal Antibodies in Treatment of COVID-19
August 2021
Casirivimab/imdevimab will be the second monoclonal antibody treatment authorized for OUTpatients with COVID-19.
This combo will be an alternative to bamlanivimab as a single-dose IV infusion. And more are in the works.
These "mabs" block SARS-CoV-2 from entering cells.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive